{
  "company": "Pacific Biosciences",
  "ticker": "PACB",
  "period": {
    "from": "2026-03-23",
    "to": "2026-04-22",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 20,
    "negative": 15,
    "neutral": 35
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Pacific Biosciences (PACB) from 2026-03-23 to 2026-04-22. Analyzed 70 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "Single Cell Sequencing Market Outlook Report 2026-2035 - North America Dominates Market Share, Global Expansion Expected",
      "date": "2026-04-20",
      "source": "news",
      "score": 0.941
    },
    {
      "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
      "date": "2026-03-27",
      "source": "news",
      "score": 0.637
    },
    {
      "title": "Reduced legacy precipitation decreases microbial community growth efficiency and alters soil organic carbon in a California grassland.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": 0.625
    },
    {
      "title": "Pacific Biosciences stock (US6932471010): Is long-read sequencing strong enough to unlock biotech up",
      "date": "2026-04-18",
      "source": "alpha_vantage",
      "score": 0.511
    },
    {
      "title": "Scaling genomic reanalysis to unlock diagnoses and transform rare disease care.",
      "date": "2026 Apr 9",
      "source": "pubmed",
      "score": 0.494
    },
    {
      "title": "Sumitomo Mitsui Trust Group Inc. Lowers Position in Pacific Biosciences of California, Inc. $PACB",
      "date": "2026-04-18",
      "source": "alpha_vantage",
      "score": 0.421
    },
    {
      "title": "Effects of 16S rRNA hypervariable region selection on respiratory microbiome profiling in healthy adults.",
      "date": "2026 Apr 3",
      "source": "pubmed",
      "score": 0.402
    },
    {
      "title": "Pacific Biosciences (NASDAQ: PACB) officer sells 88,185 shares for taxes",
      "date": "2026-04-03",
      "source": "alpha_vantage",
      "score": 0.296
    },
    {
      "title": "Here’s Why PacBio Shares Deserve a Place in Your Portfolio Today",
      "date": "2026-04-01",
      "source": "alpha_vantage",
      "score": 0.296
    },
    {
      "title": "Vanguard amendment shows 0 PACB shares after realignment (PACB)",
      "date": "2026-03-27",
      "source": "alpha_vantage",
      "score": 0.296
    }
  ],
  "top_negative": [
    {
      "title": "Genomic analysis of human-infecting Leptospira borgpetersenii isolates in Sri Lanka: Expanded PF07598 gene family repertoire and less genome reduction than bovine isolates",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.791
    },
    {
      "title": "Pacific Biosciences of California unveils SPRQ-Nx chemistry to streamline cancer testing workflows",
      "date": "2026-04-09",
      "source": "alpha_vantage",
      "score": -0.66
    },
    {
      "title": "Powering cancer testing research with HiFi whole genome sequencing and targeted panels",
      "date": "2026-04-02",
      "source": "alpha_vantage",
      "score": -0.66
    },
    {
      "title": "Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.637
    },
    {
      "title": "Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates",
      "date": "2026-03-28",
      "source": "alpha_vantage",
      "score": -0.518
    },
    {
      "title": "From genome to therapy: How HiFi long-read sequencing is helping to accelerate next-generation cancer drug research and development",
      "date": "2026-04-17",
      "source": "alpha_vantage",
      "score": -0.494
    },
    {
      "title": "Pacific Biosciences of California reveals unified approach to structural variant detection in cancer research",
      "date": "2026-04-19",
      "source": "alpha_vantage",
      "score": -0.421
    },
    {
      "title": "How SPRQ-Nx enables a single genomic workflow to help reduce costs in cancer detection techniques",
      "date": "2026-04-09",
      "source": "alpha_vantage",
      "score": -0.402
    },
    {
      "title": "PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples",
      "date": "2026-04-16",
      "source": "alpha_vantage",
      "score": -0.382
    },
    {
      "title": "Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.296
    }
  ],
  "raw_data": {
    "total_items": 70,
    "items": [
      {
        "source": "alpha_vantage",
        "title": "PacBio (PACB) Partners with Lucid Genomics for Enhanced Data Analysis",
        "url": "https://www.gurufocus.com/news/8806550/pacbio-pacb-partners-with-lucid-genomics-for-enhanced-data-analysis",
        "date": "2026-04-21",
        "summary": "PacBio (PACB) has partnered with Lucid Genomics, integrating the latter into its PacBio Compatible partner program to enhance tertiary data analysis for long-read sequencing technologies. This collaboration aims to provide improved diagnostic insights by leveraging Lucid Genomics' solutions, which are designed for PacBio's sequencing platforms. Despite PacBio's growth potential (GF Score™ of 63/100, Growth Rank 6/10), the company faces significant challenges in financial strength and profitabili",
        "sentiment_score": 0.132135,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California names Lucid Genomics as official partner for HiFi sequencing analysis",
        "url": "https://tradersunion.com/news/companies/show/1921917-pacbio-lucid-partnership/",
        "date": "2026-04-21",
        "summary": "Pacific Biosciences of California has partnered with Lucid Genomics to enhance the tertiary analysis of HiFi sequencing data, broadening tool availability for interpreting long-read sequencing in biological research. This collaboration aims to accelerate the adoption and utility of long-read genomic data analysis within the scientific community. Pacific Biosciences has also recently introduced new HiFi sequencing and Vega system oncology workflow solutions and technology to detect complex cancer",
        "sentiment_score": 0.43881,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "New PacBio software tie-up aims to turn sequencing data into reports",
        "url": "https://www.stocktitan.net/news/PACB/pac-bio-and-lucid-genomics-announce-compatibility-collaboration-to-pd8k5rot8sda.html",
        "date": "2026-04-21",
        "summary": "PacBio and Lucid Genomics have announced a compatibility collaboration to integrate Lucid Genomics' tertiary analysis platform with PacBio HiFi long-read sequencing. This partnership aims to streamline the analysis of genomic data, providing validated workflows from variant calling to clinical interpretation and methylation analysis. The collaboration is expected to reduce integration risk and accelerate time-to-insight for laboratories using PacBio systems by turning complex sequencing data int",
        "sentiment_score": 0.316609,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PacBio and Lucid Genomics Announce Compatibility Collaboration to Advance Tertiary Analysis for Long-Read Sequencing",
        "url": "https://www.marketscreener.com/news/pacbio-and-lucid-genomics-announce-compatibility-collaboration-to-advance-tertiary-analysis-for-long-ce7f59dbdb8bf023",
        "date": "2026-04-21",
        "summary": "PacBio and Lucid Genomics have announced a collaboration to advance tertiary analysis for long-read sequencing, with Lucid Genomics joining the PacBio Compatible partner program. This partnership aims to streamline the annotation, interpretation, and reporting of genomic variants from PacBio's HiFi sequencing data, transforming it into meaningful and actionable genomic insights for clinical and research applications. The compatibility will provide laboratories with a validated pipeline from sequ",
        "sentiment_score": 0.433027,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California reveals unified approach to structural variant detection in cancer research",
        "url": "https://tradersunion.com/news/companies/show/1911945-cancer-sequencing-innovation/",
        "date": "2026-04-19",
        "summary": "Pacific Biosciences of California (PacBio) is advancing cancer drug research and development by introducing its HiFi sequencing technology, which offers a unified view of structural variants and isoforms often missed by traditional methods. This technology aims to accelerate innovation in cancer therapeutics. Additionally, PacBio launched its SMRT Grant program to support researchers utilizing its sequencing solutions in oncology.",
        "sentiment_score": 0.407249,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PacBio Stock (PACB) Opinions on Covaris FFPE Workflow Announcement",
        "url": "https://www.quiverquant.com/news/PacBio+Stock+%28PACB%29+Opinions+on+Covaris+FFPE+Workflow+Announcement",
        "date": "2026-04-18",
        "summary": "PacBio's new joint workflow with Covaris for FFPE tumor samples has generated significant discussion, with enthusiasts highlighting its potential for oncology research and structural variant detection. However, this optimism is tempered by Barclays' downgrade of PacBio's target price to $1 and concerns about commercialization risks and competition. Insider trading activity shows significant sales by PacBio insiders, and hedge fund activity includes both additions and removals of PacBio stock, re",
        "sentiment_score": -0.408921,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Sumitomo Mitsui Trust Group Inc. Lowers Position in Pacific Biosciences of California, Inc. $PACB",
        "url": "https://www.marketbeat.com/instant-alerts/filing-sumitomo-mitsui-trust-group-inc-lowers-position-in-pacific-biosciences-of-california-inc-pacb-2026-04-18/",
        "date": "2026-04-18",
        "summary": "Sumitomo Mitsui Trust Group Inc. reduced its stake in Pacific Biosciences of California (NASDAQ:PACB) by 10.0% in Q4, selling 868,978 shares and now owning 7,808,580 shares valued at $14.6 million. This trimming comes amidst significant insider selling, with insiders offloading 729,711 shares in the last 90 days, raising concerns about insider sentiment as their ownership stands at only 2.50%. Analyst opinions are mixed, with a consensus \"Hold\" rating and an average price target of $1.67, rangin",
        "sentiment_score": -0.22055,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 0.956754,
        "sentiment": {
          "label": "positive",
          "score": 0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences stock (US6932471010): Is long-read sequencing strong enough to unlock biotech up",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/pacific-biosciences-stock-us6932471010-is-long-read-sequencing-strong/69190491",
        "date": "2026-04-18",
        "summary": "Pacific Biosciences (PacBio) is positioned as a leader in long-read DNA sequencing, providing technology crucial for complex genomics research such as oncology and rare diseases. The company's business model relies on high-margin consumables after initial instrument sales, with a focus on accuracy and R&D. While facing competition and execution risks, PacBio benefits from growing demand in precision medicine and strategic expansion, particularly in the US and other English-speaking markets.",
        "sentiment_score": 0.476272,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.511,
          "confidence": 0.51
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of \"Hold\" from Brokerages",
        "url": "https://www.marketbeat.com/instant-alerts/pacific-biosciences-of-california-inc-nasdaqpacb-receives-average-rating-of-hold-from-brokerages-2026-04-18/",
        "date": "2026-04-18",
        "summary": "Pacific Biosciences of California, Inc. (NASDAQ:PACB) has received a consensus \"Hold\" rating from five brokerages, with an average 12-month price target of $1.6667. Despite beating quarterly EPS estimates, the company remains unprofitable with significant negative net margin and return on equity, and analysts project a negative EPS for the current year. Insider selling has also been noted, with over $1.16 million in shares sold by insiders in the last 90 days.",
        "sentiment_score": 0.045855,
        "sentiment_label": "Neutral",
        "relevance_score": 0.305559,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "From genome to therapy: How HiFi long-read sequencing is helping to accelerate next-generation cancer drug research and development",
        "url": "https://www.pacb.com/blog/from-genome-to-therapy-how-hifi-long-read-sequencing-is-helping-to-accelerate-next-generation-cancer-drug-research-and-development/",
        "date": "2026-04-17",
        "summary": "HiFi long-read sequencing offers a comprehensive approach to cancer drug development by providing detailed genomic, transcriptomic, and epigenetic insights. This technology enables better detection of complex structural variants, improves neoantigen discovery for immunotherapies, and characterizes epigenetic dysregulation. By integrating these multiomic data, HiFi sequencing can accelerate target identification, biomarker validation, and the development of precision medicines and advanced cell t",
        "sentiment_score": 0.423941,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PacBio to Report First Quarter 2026 Financial Results on May 7, 2026",
        "url": "https://www.sahmcapital.com/news/content/pacbio-to-report-first-quarter-2026-financial-results-on-may-7-2026-2026-04-16",
        "date": "2026-04-17",
        "summary": "PacBio (NASDAQ: PACB) announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026. The company will host a conference call and webcast to discuss the results at 4:30 p.m. Eastern Time, accessible via its investor relations website. PacBio is a life science technology company specializing in advanced sequencing solutions for various research applications.",
        "sentiment_score": 0.004718,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PacBio and Covaris Announce Joint Workflow Enabling HiFi Long-Read Sequencing of FFPE Tumor Samples",
        "url": "https://www.sahmcapital.com/news/content/pacbio-and-covaris-announce-joint-workflow-enabling-hifi-long-read-sequencing-of-ffpe-tumor-samples-2026-04-15",
        "date": "2026-04-16",
        "summary": "PacBio and Covaris have developed a joint workflow that enables highly accurate HiFi long-read sequencing from formalin-fixed, paraffin-embedded (FFPE) tissue samples, which are crucial for cancer research. This innovative solution addresses historical limitations caused by DNA damage in FFPE samples by combining Covaris' truXTRAC extraction technology with PacBio's Kinnex library preparation and Revio system sequencing, leading to superior detection of structural and small variants compared to ",
        "sentiment_score": 0.476508,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PacBio to Report First Quarter 2026 Financial Results on May 7, 2026",
        "url": "https://www.marketscreener.com/news/pacbio-to-report-first-quarter-2026-financial-results-on-may-7-2026-ce7e50d2d88bfe25",
        "date": "2026-04-16",
        "summary": "PacBio (NASDAQ: PACB) announced that it will host a quarterly conference call to discuss its first quarter 2026 financial results on Thursday, May 7, 2026, at 4:30 p.m. Eastern Time. The call will be webcast and accessible via the company's investor relations website, providing details on their advanced sequencing solutions. PacBio focuses on designing, developing, and manufacturing technologies like HiFi long-read sequencing to resolve complex genetic problems across various research applicatio",
        "sentiment_score": 0.044931,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "May 7: PacBio investors get first-quarter results call and webcast",
        "url": "https://www.stocktitan.net/news/PACB/pac-bio-to-report-first-quarter-2026-financial-results-on-may-7-le5d5m1659u4.html",
        "date": "2026-04-16",
        "summary": "PacBio (NASDAQ: PACB) will hold a conference call on May 7, 2026, at 4:30 p.m. ET to discuss its first-quarter 2026 financial results. The call will be webcast live on the company's investor relations website, with toll-free and international dial-in options available. Historically, similar pre-earnings announcements for PACB have been followed by a negative market reaction, indicating investors often reposition themselves based on these updates.",
        "sentiment_score": 0.043278,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Why Pacific Biosciences of California (PACB) outpaced the stock market today",
        "url": "https://www.msn.com/en-us/money/markets/why-pacific-biosciences-of-california-pacb-outpaced-the-stock-market-today/ar-AA20Z8yS",
        "date": "2026-04-16",
        "summary": "This article provides a brief update on why Pacific Biosciences of California (PACB) performed better than the overall stock market. Unfortunately, the full content of the article is missing, preventing a detailed summary of the reasons for its outperformance.",
        "sentiment_score": 0.715551,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Archived tumor samples gain long-read DNA workflow with 60% phasing",
        "url": "https://www.stocktitan.net/news/PACB/pac-bio-and-covaris-announce-joint-workflow-enabling-hi-fi-long-read-utgm6zkcc09k.html",
        "date": "2026-04-15",
        "summary": "PacBio and Covaris have developed a joint workflow for HiFi long-read sequencing of FFPE tumor samples, enabling researchers to extract longer DNA fragments from archived tissues. This new method, integrating Covaris truXTRAC and PacBio Kinnex, produced over 100 million HiFi reads per sample with significant structural variant detection and approximately 60% variant phasing. It aims to accelerate discoveries in cancer biology by unlocking valuable insights from previously challenging FFPE sample",
        "sentiment_score": 0.405734,
        "sentiment_label": "Bullish",
        "relevance_score": 0.977463,
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Barclays Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.00",
        "url": "https://www.marketbeat.com/instant-alerts/barclays-lowers-pacific-biosciences-of-california-nasdaqpacb-price-target-to-100-2026-04-14/",
        "date": "2026-04-15",
        "summary": "Barclays has lowered its price target for Pacific Biosciences of California (NASDAQ:PACB) from $1.50 to $1.00, maintaining an \"underweight\" rating due to the company's unprofitability and poor financial metrics. The report highlights significant insider selling and mixed analyst ratings, with the stock actively traded at $1.56. Despite beating quarterly EPS estimates, the company shows negative returns on equity and net margins.",
        "sentiment_score": -0.429715,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California fosters connections and momentum at PacBioPRISM event",
        "url": "https://tradersunion.com/news/companies/show/1889518-pacbio-barcelona-conference/",
        "date": "2026-04-15",
        "summary": "Pacific Biosciences of California concluded the first day of its PacBioPRISM conference with a networking reception in Barcelona, aiming to build further engagement. The company previously introduced HiFi sequencing, offering over 99.9% accuracy, and presented its HiFi sequencing and Vega system at AACR26 for oncology workflow technology advancements. These developments were shared with industry professionals during the current conference.",
        "sentiment_score": 0.415612,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences (PACB) Garnering Attention Amid Involvement in Trillion Gene Atlas Program",
        "url": "https://www.insidermonkey.com/blog/pacific-biosciences-pacb-garnering-attention-amid-involvement-in-trillion-gene-atlas-program-1737409/?amp=1",
        "date": "2026-04-14",
        "summary": "Pacific Biosciences (NASDAQ: PACB) is gaining attention due to its involvement in the Trillion Gene Atlas program, where its Revio platform will be used by Basecamp Research to generate a large metagenomics database. Despite this advancement, Barclays recently downgraded PACB's price target and rating, citing expectations of a difficult market and a potential temporary drop in consumable sales due to competitive launches and client anticipation of a new platform. The company specializes in desig",
        "sentiment_score": -0.227889,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 0.959776,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) registers a bigger fall than the market: Important facts to note",
        "url": "https://www.msn.com/en-us/money/top-stocks/pacific-biosciences-of-california-pacb-registers-a-bigger-fall-than-the-market-important-facts-to-note/ar-AA1ZzkkC?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-14",
        "summary": "This article analyzes why Pacific Biosciences of California (PACB) experienced a larger decline than the overall market, emphasizing the importance of considering various factors beyond a simple price drop. It suggests that investors should look into the company's fundamentals, recent developments, and market sentiment to understand the implications of the stock's performance. The article implies that a deeper dive is necessary to determine if the stock presents a buying opportunity or a warning",
        "sentiment_score": -0.400351,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1",
        "url": "https://www.moomoo.com/news/post/68285885/barclays-maintains-pacific-biosciences-of-california-pacbus-with-sell-rating",
        "date": "2026-04-14",
        "summary": "Barclays has reiterated its Sell rating on Pacific Biosciences of California (PACB.US) and significantly lowered its price target to $1. This adjustment reflects continued analyst pessimism regarding the company's financial outlook and market position.",
        "sentiment_score": -0.421705,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) Suffers a Larger Drop Than the General Market: Key Insights",
        "url": "https://www.msn.com/en-us/money/topstocks/pacific-biosciences-of-california-pacb-suffers-a-larger-drop-than-the-general-market-key-insights/ar-AA1Jxhbx?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-14",
        "summary": "Pacific Biosciences of California (PACB) stock experienced a drop of 1.15% in the last trading session, underperforming the S&P 500's 0.21% gain. This recent decline builds on a difficult year for PACB, which has seen its shares fall 18.06% year-to-date, contrasting with the S&P 500's 6.27% gain. The article highlights upcoming earnings, fundamental valuation metrics, and analyst revisions as key factors to watch for investors.",
        "sentiment_score": -0.223991,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California introduces expanded long-read assay to streamline clinical workflows",
        "url": "https://tradersunion.com/news/companies/show/1882956-pacbio-long-read-assays/",
        "date": "2026-04-13",
        "summary": "Pacific Biosciences of California (PacBio) has launched an updated pre-clinical playbook to enhance clinical laboratory workflows using accurate, comprehensive long-read assay approaches for Laboratory Developed Tests (LDTs). This initiative aims to provide more thorough and reliable testing methodologies for clinical genomics and research laboratories. PacBio is showcasing these new solutions at the AACR annual meeting, building on its previous advancements in HiFi sequencing technology.",
        "sentiment_score": 0.444081,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (NasdaqGS:PACB) Stock Forecast & Analyst Predictions",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pacb/pacific-biosciences-of-california/future",
        "date": "2026-04-13",
        "summary": "Pacific Biosciences of California (PACB) is projected to experience significant growth, with earnings and revenue expected to increase by 39.2% and 10.9% per annum respectively. Despite this growth, analysts anticipate the company will remain unprofitable for the next three years. Recent updates include a price target increase to US$2.50, several insider stock sales, and announcements of new product developments and scientific advancements.",
        "sentiment_score": 0.101577,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California unveils step-by-step HiFi sequencing process leveraging Revio and Vega platforms",
        "url": "https://tradersunion.com/news/companies/show/1875342-pacbio-hifi-workflow/",
        "date": "2026-04-11",
        "summary": "Pacific Biosciences of California has introduced a comprehensive five-step workflow for its HiFi sequencing technology, utilizing the Revio and Vega platforms. This guide aims to simplify the sequencing process for researchers, covering everything from DNA extraction to data analysis. The initiative follows previous efforts by the company to enhance genomic analysis capabilities, particularly in cancer research.",
        "sentiment_score": 0.461626,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Director Christopher Gibson receives options and RSUs at Pacific Biosciences (PACB)",
        "url": "https://www.stocktitan.net/sec-filings/PACB/form-4-pacific-biosciences-of-california-inc-insider-trading-activity-d36d0ecadcf6.html",
        "date": "2026-04-10",
        "summary": "Christopher Gibson, a director at Pacific Biosciences (PACB), recently received equity awards including stock options for 77,842 shares at an exercise price of $1.52, and 57,473 restricted stock units (RSUs). These awards are tied to his Board appointment on March 3, 2026, and are subject to multi-year vesting schedules contingent on his continued service. Following these grants, Gibson directly holds 111,386 shares of Common Stock.",
        "sentiment_score": 0.101408,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California unveils SPRQ-Nx chemistry to streamline cancer testing workflows",
        "url": "https://tradersunion.com/news/companies/show/1867932-cancer-genomics-consolidation/",
        "date": "2026-04-09",
        "summary": "Pacific Biosciences of California has introduced its new SPRQ-Nx chemistry, designed to enhance cancer testing workflows by combining several assays into a single HiFi genomic workflow. This innovation aims to reduce laboratory costs and accelerate result delivery, addressing common inefficiencies in traditional cancer diagnostic processes. The company previously laid the groundwork for this advancement with its HiFi sequencing and PacBio HiFi technology, which provided detailed insights into ca",
        "sentiment_score": 0.462116,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "How SPRQ-Nx enables a single genomic workflow to help reduce costs in cancer detection techniques",
        "url": "https://www.pacb.com/blog/how-sprq-nx-enables-a-single-genomic-workflow-to-help-reduce-costs-in-cancer-detection-techniques/",
        "date": "2026-04-09",
        "summary": "The article discusses how PacBio's SPRQ-Nx chemistry and Revio system can significantly reduce the costs and inefficiencies associated with cancer detection by consolidating multiple specialized assays into a single, comprehensive genomic workflow. This approach aims to provide clearer, faster results for patients and clinicians, streamlining laboratory operations and lowering financial burdens. By shifting from fragmented testing to a HiFi genomic workflow, it enables a more complete view of th",
        "sentiment_score": 0.449491,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) laps the stock market: Here's why",
        "url": "http://www.msn.com/en-us/money/top-stocks/pacific-biosciences-of-california-pacb-laps-the-stock-market-here-s-why/ar-AA20mKVE?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-04-08",
        "summary": "This article from MSN focuses on Pacific Biosciences of California (PACB) and its stock market performance, highlighting why the company is outperforming. It delves into the factors contributing to PACB's strong performance, suggesting reasons for investor interest and market outperformance. The content provided is minimal, indicating a missing article body.",
        "sentiment_score": 0.403325,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) Outperforms the Market: The Reasons Explained",
        "url": "https://www.bitget.com/news/detail/12560605345823",
        "date": "2026-04-08",
        "summary": "Pacific Biosciences of California (PACB) has recently outperformed the market, with its shares increasing by 1.41% in its latest trading session and rising 2.16% over the past month. Analysts anticipate an EPS of -$0.17 for the upcoming earnings report and a full-year revenue of $175.4 million, with the company currently holding a Zacks Rank of #1 (Strong Buy). This strong performance is attributed to positive analyst estimate trends and its favorable position within the Medical - Instruments in",
        "sentiment_score": 0.319266,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PacBio HiFi WGS resolves hidden disease-linked structural variants in diverse populations",
        "url": "https://tradersunion.com/news/companies/show/1853775-hifi-wgs-disease-variants/",
        "date": "2026-04-08",
        "summary": "Pacific Biosciences of California is advancing disease detection by utilizing its PacBio HiFi whole genome sequencing (WGS) technology to identify complex structural variants (SVs) across various populations. This method, highlighted in a recent webinar by Dr. Michael Schatz, improves accuracy in uncovering disease-linked genomic regions. The company has also expanded its HiFi sequencing applications to include detailed cancer variation analysis and mapping of structural variants and novel isofo",
        "sentiment_score": 0.027203,
        "sentiment_label": "Neutral",
        "relevance_score": 0.33251,
        "sentiment": {
          "label": "positive",
          "score": 0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) Outperforms the Market: The Reasons Explained",
        "url": "https://www.bitget.com/amp/news/detail/12560605345823",
        "date": "2026-04-07",
        "summary": "Pacific Biosciences of California (PACB) recently outperformed the market, with its stock rising 1.41% as the S&P 500 saw only a modest gain. The company's shares also increased by 2.16% over the last month, against a declining Medical sector. Analysts anticipate PACB will report an EPS of -$0.17 and revenue of $41 million for the upcoming quarter, and currently holds a Zacks Rank of #1 (Strong Buy), indicating strong prospects.",
        "sentiment_score": 0.503332,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) Outperforms the Market: The Reasons Explained",
        "url": "https://www.bitget.com/asia/news/detail/12560605345823",
        "date": "2026-04-07",
        "summary": "Pacific Biosciences of California (PACB) has recently outperformed the market, closing with a 1.41% increase and surpassing the S&P 500. Over the past month, PACB shares rose 2.16%, exceeding both the Medical sector and the S&P 500. The company, which holds a Zacks Rank of #1 (Strong Buy), is anticipated to report an EPS of -$0.17 and total revenue of $41 million for its upcoming earnings announcement.",
        "sentiment_score": 0.536633,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Here's why you should add PacBio stock to your portfolio now",
        "url": "https://www.msn.com/en-us/money/topstocks/heres-why-you-should-add-pacbio-stock-to-your-portfolio-now/ar-AA1ZVDpr",
        "date": "2026-04-05",
        "summary": "This article argues for adding PacBio stock to an investment portfolio.",
        "sentiment_score": 0.525783,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California traces DNA sequencing evolution from Sanger to HiFi platforms",
        "url": "https://tradersunion.com/news/companies/show/1842723-dna-sequencing-innovation/",
        "date": "2026-04-04",
        "summary": "Pacific Biosciences of California (PacBio) is advancing DNA sequencing from traditional Sanger methods to its powerful HiFi long-read platforms. The company emphasizes the rapid evolution within genomics, urging scientists to embrace new innovations for more accurate and comprehensive genetic analysis. PacBio's HiFi technology offers detailed insights into cancer variation and allows mapping of structural variants and novel isoforms in cancer genomics on a single platform, enhancing both researc",
        "sentiment_score": 0.40965,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences (NASDAQ: PACB) officer sells 88,185 shares for taxes",
        "url": "https://www.stocktitan.net/sec-filings/PACB/form-4-pacific-biosciences-of-california-inc-insider-trading-activity-6b0b20296022.html",
        "date": "2026-04-03",
        "summary": "James R. Gibson II, an officer at Pacific Biosciences (NASDAQ: PACB), reported an open-market sale of 88,185 shares at a weighted average price of $1.37 per share. These shares were mandatorily sold to cover tax withholding obligations linked to the vesting of restricted stock units. After this transaction, Gibson still directly holds 1,245,663 shares of common stock.",
        "sentiment_score": 0.009809,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California Inc expected to post a loss of 13 cents a share - Earnings Preview",
        "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N40M0CT:0-pacific-biosciences-of-california-inc-expected-to-post-a-loss-of-13-cents-a-share-earnings-preview/",
        "date": "2026-04-03",
        "summary": "Pacific Biosciences of California Inc (PACB) is projected to report a loss of 13 cents per share. This financial forecast comes from Refinitiv as part of an earnings preview. The article provides a brief overview of the expected performance for the company.",
        "sentiment_score": -0.241059,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Powering cancer testing research with HiFi whole genome sequencing and targeted panels",
        "url": "https://www.pacb.com/blog/powering-cancer-testing-research-with-hifi-whole-genome-sequencing-and-targeted-panels/",
        "date": "2026-04-02",
        "summary": "The article discusses how HiFi whole genome sequencing (WGS) and targeted panels are advancing cancer testing research. It highlights that HiFi technology provides accurate multiomic sequencing, offering a more complete view of the cancer genome, transcriptome, and epigenome, which is crucial for detecting complex variants often missed by standard approaches. The piece also details how partnerships with industry leaders like Agilent and QIAGEN extend the capabilities of HiFi sequencing for compr",
        "sentiment_score": 0.027236,
        "sentiment_label": "Neutral",
        "relevance_score": 0.340422,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "[144] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. SEC Filing",
        "url": "https://www.stocktitan.net/sec-filings/PACB/144-pacific-biosciences-of-california-inc-sec-filing-989e6dbe1ee2.html",
        "date": "2026-04-01",
        "summary": "This article details a Form 144 SEC filing by Pacific Biosciences of California, Inc. (PACB) for a proposed sale of securities. The filing indicates the sale of 88,185 common shares acquired as restricted stock on March 31, 2026, through Morgan Stanley Smith Barney LLC. The article provides the market value, outstanding shares, and emphasizes the filer's representation that they are unaware of any material adverse, undisclosed information concerning the issuer.",
        "sentiment_score": 0.011826,
        "sentiment_label": "Neutral",
        "relevance_score": 0.312816,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Here’s Why PacBio Shares Deserve a Place in Your Portfolio Today",
        "url": "https://www.bitget.com/amp/news/detail/12560605327622",
        "date": "2026-04-01",
        "summary": "PacBio (PACB) is highlighted as a strong buy due to its innovative sequencing technology, expanding product portfolio with Revio and Vega systems, and consistent financial performance that has exceeded expectations. Despite challenges with extended sales cycles and academic funding limitations, analyst estimates for 2026 show improving sentiment, with projected revenue growth and a narrowed loss per share. The company's leadership in the growing SMRT technology market and strategic collaboration",
        "sentiment_score": 0.019179,
        "sentiment_label": "Neutral",
        "relevance_score": 0.347125,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Powered by PacBio: Selected publications from January – March 2026",
        "url": "https://www.pacb.com/blog/powered-by-pacbio-selected-publications-from-january-march-2026/",
        "date": "2026-04-01",
        "summary": "This article showcases selected research publications from January to March 2026, highlighting the diverse applications of PacBio HiFi sequencing in areas like rare disease, cancer, and transcriptomics. It details how the technology is revealing new insights into ALS transcript biology, enabling advanced machine learning in cancer research, and improving diagnostics for rare genetic disorders through comprehensive genomic and transcriptomic analysis. The studies demonstrate the advantages of lon",
        "sentiment_score": 0.818806,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California unveils oncology workflow solutions at industry event",
        "url": "https://tradersunion.com/news/companies/show/1827511-pacbio-aacr26-oncology/",
        "date": "2026-04-01",
        "summary": "Pacific Biosciences of California is presenting its HiFi sequencing technology and Vega system at the AACR26 conference in San Diego. The company aims to showcase how its solutions can enhance oncology workflows and provide comprehensive insights into cancer biology with high accuracy. This demonstration builds on previous advancements in HiFi sequencing for detailed cancer variation analysis and automated epigenetic data detection.",
        "sentiment_score": 0.44207,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.178,
          "confidence": 0.18
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PACB PE Ratio & Valuation, Is PACB Overvalued",
        "url": "https://intellectia.ai/en/stock/PACB/valuation",
        "date": "2026-04-01",
        "summary": "This article analyzes the valuation of Pacific Biosciences of California Inc (PACB), suggesting it is currently in the \"Fair zone\" with a forward PS ratio of 3.24. It provides a fair price range between $0.88 and $8.71 based on relative valuation. However, it also notes that PACB's P/B ratio is significantly higher than its historical averages and its P/S ratio, while below competitors, still appears unsustainable given its revenue growth.",
        "sentiment_score": -0.221403,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences Stock: Long-Read Sequencing Leader Faces Evolving Genomics Landscape",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/pacific-biosciences-stock-long-read-sequencing-leader-faces-evolving/69027808",
        "date": "2026-03-30",
        "summary": "Pacific Biosciences (PacBio) is a leader in long-read DNA sequencing technology, positioning itself centrally in the expanding genomics sector with its Revio and Onso systems. The company's technology offers high accuracy for complex genomic analysis, crucial for applications in human genomics, infectious diseases, and plant breeding. While operating in a competitive market, PacBio maintains its edge through technological innovation, strategic partnerships, and recurring revenue from consumables",
        "sentiment_score": 0.324146,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) registers a bigger fall than the market: Important facts to note",
        "url": "https://www.msn.com/en-us/money/topstocks/pacific-biosciences-of-california-pacb-registers-a-bigger-fall-than-the-market-important-facts-to-note/ar-AA1ZzkkC",
        "date": "2026-03-28",
        "summary": "This article analyzes why Pacific Biosciences of California (PACB) experienced a more significant market decline, highlighting key financial and operational details that may have contributed to its underperformance compared to the broader market. It suggests that investors should consider specific factors influencing PACB's stock.",
        "sentiment_score": -0.254964,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "PacBio (PACB) Q2 Earnings Report Preview: What To Look For",
        "url": "https://www.msn.com/en-us/money/companies/pacbio-pacb-q2-earnings-report-preview-what-to-look-for/ar-AA1JZciG?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-28",
        "summary": "This article provides a preview of PacBio's upcoming Q2 earnings report, highlighting key metrics and expectations. Investors are anticipating robust revenue growth and an update on the company's financial performance. The report will be crucial for assessing PacBio's market position and future outlook in the genomics sector.",
        "sentiment_score": 0.035896,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates",
        "url": "http://www.msn.com/en-us/money/topstocks/pacific-biosciences-of-california-pacb-reports-q2-loss-beats-revenue-estimates/ar-AA1K7v8O?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1",
        "date": "2026-03-28",
        "summary": "Pacific Biosciences of California (PACB) reported a narrower-than-expected loss in its second quarter, although it still posted a non-GAAP diluted net loss per share of $0.23. The company successfully beat revenue estimates, recording $38.03 million against an expected $34.79 million. Despite this revenue beat, the firm's stock has seen a significant year-to-date decline.",
        "sentiment_score": 0.200593,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.518,
          "confidence": 0.52
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider",
        "url": "https://www.bitget.com/asia/news/detail/12560605312305",
        "date": "2026-03-28",
        "summary": "Pacific Biosciences of California (PACB) recently experienced a significant stock price drop, falling 6.67% to $1.26 while the broader market saw smaller declines. Over the past month, PACB's stock decreased 24.16%, outpacing the Medical sector's 7.36% and the S&P 500's 6.15% losses. Despite this, the company holds a Zacks Rank of #1 (Strong Buy) within the Medical – Instruments industry, with analysts anticipating a 10.36% increase in revenue for the upcoming quarter, despite a projected 13.33%",
        "sentiment_score": -0.210211,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Vanguard amendment shows 0 PACB shares after realignment (PACB)",
        "url": "https://www.stocktitan.net/sec-filings/PACB/schedule-13g-a-pacific-biosciences-of-california-inc-amended-passive--193c9cb0abec.html",
        "date": "2026-03-27",
        "summary": "The Vanguard Group filed an amendment to its Schedule 13G/A for Pacific Biosciences of California Inc (PACB), reporting 0 shares beneficially owned as of March 13, 2026. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report their beneficial ownership separately. The filing confirms that The Vanguard Group no longer holds beneficial ownership over these securities.",
        "sentiment_score": 0.033742,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Pacific Biosciences of California (PACB) Experiences a Sharper Decline Compared to the Market: Key Points to Consider",
        "url": "https://www.bitget.com/amp/news/detail/12560605312305",
        "date": "2026-03-27",
        "summary": "Pacific Biosciences of California (PACB) recently saw its stock price drop by 6.67% to $1.26, underperforming major market indices like the S&P 500, Dow Jones, and Nasdaq. Over the last month, PACB's stock has declined by 24.16%, significantly more than its sector average. Despite negative earnings per share projections for the upcoming report, analysts anticipate revenue growth, and the company currently holds a Zacks Rank of #1 (Strong Buy).",
        "sentiment_score": -0.238703,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Single Cell Sequencing Market Outlook Report 2026-2035 - North America Dominates Market Share, Global Expansion Expected",
        "description": "Key growth drivers include technological advancements, reduced sequencing costs, and increased interest from academia and pharmaceuticals Key growth drivers include technological advancements, reduced sequencing costs, and increased interest from academia and…",
        "url": "https://www.globenewswire.com/news-release/2026/04/20/3277309/28124/en/Single-Cell-Sequencing-Market-Outlook-Report-2026-2035-North-America-Dominates-Market-Share-Global-Expansion-Expected.html",
        "date": "2026-04-20",
        "published_at": "2026-04-20T16:17:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.941,
          "confidence": 0.94
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Dominance modifiers at the Arabidopsis self-incompatibility locus retain proto-miRNA features and act through non-canonical pathways",
        "description": "Author summary Many plants avoid self-fertilization through a system of self-incompatibility, which allows them to recognize and reject their own pollen. In plants like those in the Arabidopsis family, self-incompatibility operates through a “lock-and-key” sy…",
        "url": "https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012127",
        "date": "2026-04-20",
        "published_at": "2026-04-20T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "ntStat: k-mer characterization using occurrence statistics in raw sequencing data",
        "description": "Author summary Characterizing an organism’s genome from raw sequencing data is a foundational step in biological research, informing disease studies and evolutionary analysis. This process often relies on counting short DNA substrings, i.e., k-mers, to estima…",
        "url": "https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1014158",
        "date": "2026-04-01",
        "published_at": "2026-04-01T14:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Wilms Tumor Protein Market Outlook 2026-2030 and 2035 Shows 6.9% CAGR as Rising Investment in Oncology Research Accelerates Industry Growth",
        "description": "Dublin, March 31, 2026 (GLOBE NEWSWIRE) -- The \"Wilms Tumor Protein Market Report 2026\" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, covering market statistics, regional shares, competitor data, market seg…",
        "url": "https://www.globenewswire.com/news-release/2026/03/31/3265766/28124/en/Wilms-Tumor-Protein-Market-Outlook-2026-2030-and-2035-Shows-6-9-CAGR-as-Rising-Investment-in-Oncology-Research-Accelerates-Industry-Growth.html",
        "date": "2026-03-31",
        "published_at": "2026-03-31T15:07:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
        "description": "Dublin, March  27, 2026  (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to  ResearchAndMarkets.com's offering.    ...",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:44:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "news",
        "source_name": "Plos.org",
        "title": "Genomic analysis of human-infecting Leptospira borgpetersenii isolates in Sri Lanka: Expanded PF07598 gene family repertoire and less genome reduction than bovine isolates",
        "description": "Author summary Leptospirosis is an emerging bacterial zoonosis worldwide. Leptospira borgpetersenii is a causative agent of human leptospirosis in some agricultural contexts. We address here the relatively neglected comparative genome analysis of L. borgpeter…",
        "url": "https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012540",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "pubmed",
        "pmid": "41993911",
        "title": "Genome Sequence of Arthrobacter Phage StuartMinion.",
        "authors": "Adamson MA et al.",
        "journal": "microPublication biology",
        "date": "2026-04-22",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41993911/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41980473",
        "title": "Molecular genetic analysis of a para-Bombay phenotype pedigree using PacBio sequencing technology.",
        "authors": "Wang N et al.",
        "journal": "Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis",
        "date": "2026 Apr 6",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41980473/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41964604",
        "title": "A chromosome-level genome assembly of a vernal pool specialist amphibian, the Western Spadefoot, Spea hammondii.",
        "authors": "Thompsky B et al.",
        "journal": "The Journal of heredity",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41964604/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41964077",
        "title": "Reduced legacy precipitation decreases microbial community growth efficiency and alters soil organic carbon in a California grassland.",
        "authors": "Hernandez LK et al.",
        "journal": "Microbiome",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41964077/",
        "sentiment": {
          "label": "positive",
          "score": 0.625,
          "confidence": 0.62
        }
      },
      {
        "source": "pubmed",
        "pmid": "41952156",
        "title": "Benchmarking of sequencing technologies defines optimal strategies for genetic variants detection in a human genome.",
        "authors": "Eveleigh RJM et al.",
        "journal": "Genome biology",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41952156/",
        "sentiment": {
          "label": "positive",
          "score": 0.161,
          "confidence": 0.16
        }
      },
      {
        "source": "pubmed",
        "pmid": "41949880",
        "title": "RBM20 Truncating Variants and Human Cardiomyopathy.",
        "authors": "Floyd BJ et al.",
        "journal": "JAMA cardiology",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41949880/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41936881",
        "title": "Effects of 16S rRNA hypervariable region selection on respiratory microbiome profiling in healthy adults.",
        "authors": "Liang L et al.",
        "journal": "Journal of microbiological methods",
        "date": "2026 Apr 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41936881/",
        "sentiment": {
          "label": "positive",
          "score": 0.402,
          "confidence": 0.4
        }
      },
      {
        "source": "pubmed",
        "pmid": "41912537",
        "title": "Telomere-to-telomere-level genome assembly and annotation of the Zi goose Anser cygnoides.",
        "authors": "Jiang K et al.",
        "journal": "Scientific data",
        "date": "2026 Mar 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41912537/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41879279",
        "title": "A genome assembly of the North American golden eagle, Aquila chrysaetos canadensis.",
        "authors": "Capel SLR et al.",
        "journal": "The Journal of heredity",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41879279/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41715921",
        "title": "Scaling genomic reanalysis to unlock diagnoses and transform rare disease care.",
        "authors": "Rockowitz S et al.",
        "journal": "HGG advances",
        "date": "2026 Apr 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41715921/",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "pubmed",
        "pmid": "41689457",
        "title": "PAQman: reference-free ensemble evaluation of long-read genome assemblies.",
        "authors": "O'Donnell S et al.",
        "journal": "G3 (Bethesda, Md.)",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41689457/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41677369",
        "title": "cuteHap: Haplotype-Aware Structural Variant Detection in Phased Long-Read Sequencing Data.",
        "authors": "Cao S et al.",
        "journal": "Advanced science (Weinheim, Baden-Wurttemberg, Germany)",
        "date": "2026-04-22",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41677369/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41391700",
        "title": "Evolutionary history of Ridge-nosed Rattlesnakes (Crotalus willardi): A specialized and diverse montane species.",
        "authors": "Buontempo MJ et al.",
        "journal": "Molecular phylogenetics and evolution",
        "date": "2026-04-22",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41391700/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41225292",
        "title": "Clinical Feasibility of Long-Read WGS for DNA Methylation Signature Analysis.",
        "authors": "Hildonen M et al.",
        "journal": "Clinical genetics",
        "date": "2026-04-22",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41225292/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}